- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Hepatitis Research and Treatment
Volume 2013 (2013), Article ID 860514, 4 pages
Hepatitis Viruses in Heamodialysis Patients: An Added Insult to Injury?
1Department of Microbiology, Kasturba Medical College and Hospital, Manipal University, Madhav Nagar, Manipal 576104, Karnataka, India
2Department of Nephrology, Kasturba Medical College and Hospital, Manipal University, Madhav Nagar, Manipal 576104, Karnataka, India
Received 13 December 2012; Revised 4 February 2013; Accepted 12 February 2013
Academic Editor: Piero Luigi Almasio
Copyright © 2013 Kranthi Kosaraju et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hepatitis B (HBV) and hepatitis C (HCV) viruses are the most important causes of chronic liver disease in patients with end stage renal disease on hemodialysis. The prevalence of hepatitis infection among hemodialysis patients is high and varies between countries and between dialysis units within a single country. This case-control study was undertaken to estimate the occurrence of HBV and HCV infections in patients undergoing hemodialysis in our tertiary care center. All patients receving hemodialysis at our centre with HCV or HBV infection were included in the study. The total number of patients admitted for hemodialysis during the study period was 1710. Among these, 26 patients were positive for HBV, 19 were positive for HCV, and 2 were positive for both HCV and HBV. Mean age of the infected cases in our study was 48.63 years. Mean duration of dialysis for infected cases was 4.8 years while that of the noninfected controls was 3.18 years. The mean dialysis interval was twice a week. Interventions to reduce the occurrence of these infections are of utmost need to reduce the risk of long-term complications among hemodialysis patients.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections cause morbidity and mortality in haemodialysis patients. Prolonged vascular exposure and multiple blood transfusions increase the risk of acquiring these blood-borne infections in these patients. Contaminated devices, equipments, and supplies, environmental surfaces, and attending personnel may also play a crucial role in the nosocomial transmission of these infections. Infections with hepatitis viruses in haemodialysis patients are further promoted by the significant immune status dysfunction developing due to irreversible renal compromise [1–3].
Furthermore, hepatitis viral infections in haemodialysis patients cause liver disease in renal failure patients undergoing replacement therapy. They also pose a significant problem in the management of these cases as patients with renal failure cannot clear the viruses effectively. Patients with coinfections with these viruses develop severe clinical presentations and resistance to interferon treatment .
There are very limited data available on the occurrence of such infections in haemodialysis patients from this part of the country. The present study aimed to investigate the occurrence of HBV and HCV infections in haemodialysis patients and the risk factors associated with such infections.
2. Materials and Methods
This study was conducted as a retrospective case-control study involving the haemodialysis patients at a dialysis centre of a tertiary care hospital. All the patients who underwent haemodialysis from January 2004 to June 2012 were included in the study.
Patients receiving haemodialysis were considered as a “case” for the study if their serum tested positive for either HBV or HCV. In contrast, the patients receiving haemodialysis were considered as a “control” if their serum tested negative for all the three viruses. For every case, one age- and gender-matched control receiving haemodialysis was selected.
Patients’ medical records were reviewed to obtain details like age, gender, clinical diagnosis, and duration and frequency of dialysis, history of blood transfusions, and past surgeries and these details were recorded in a preformed questionnaire for all cases and controls. Further, the results of serological tests (HBsAg, Anti-HCV antibodies), renal function tests (serum urea and creatinine), and liver function tests were recorded for both groups. The results of biochemical parameters were correlated with serological findings.
Duration of dialysis, frequency of dialysis, and the results of biochemical parameters were compared for infected cases and non-infected controls and were analyzed statistically using nonparametric tests and chi-square tests.
The present retrospective study was conducted for a period of 102 months, that is, from January 2004 to June 2012. A total of 180 patients were diagnosed to have chronic kidney disease and were on maintenance haemodialysis during the study period. Also, our dialysis unit caters to approximately 15 in-patients per month referred from other departments or hospitals for haemodialysis. Therefore, the total number of patients who received haemodialysis at our centre during the study period was 1710.
Among these patients, 45/1710 cases (2.63%) were found to be infected with either HBV or HCV and were included as cases for our study.
Out of 45 cases studied, 26/1710 (1.52%) tested positive for HBsAg and 19/1710 (1.11%) tested positive for Anti-HCV antibodies. Out of 26 cases infected with HBV, 22 (84.6%) were males and 4 (15.4%) were females. Among HCV positive cases, 18 (94.7%) were males and 1 (5.2%) was female. Among the cases, dual infection with HBV and HCV was seen in two patients, 1 male and 1 female.
Mean age of the infected cases in our study was 48.63 years. HBV infection was seen most commonly in the age group of 50–60 yrs, whereas HCV was commonest in the age group of 30–40 years.
Mean duration of dialysis for infected cases was 4.8 years while that of the non-infected controls was 3.18 years. There was a statistically significant () difference between the cases and controls with respect to duration of dialysis (Mann-Whitney test since mean was less than 2 standard deviations, non-parametric tests were used). When comparing frequency of dialysis between cases and controls, as it was a categorical variable, chi-square test was applied and there was no statistically significant () correlation of the frequency of dialysis between cases and controls.
With respect to liver function tests, a significant elevation of AST (aspartate aminotransferase) and ALT (alanine transaminase) values among infected cases () was observed in this study.
Most of the patients (80%) on haemodialysis in our study were anaemic with haemoglobin concentration <10 g% as shown in Figure 1. The comparison of haemoglobin values among cases and controls is depicted in Figure 2. With respect to renal function tests in cases and controls, mean value of blood urea for cases was 99.85 and for controls was 103.1, and mean value of creatinine was 22.3 for cases and 8.65 for controls, respectively. No statistically significant difference was observed between both groups with respect to serum levels of urea (), creatinine (), and haemoglobin ().
Risk factors for acquiring HBV and HCV infections were studied for both groups. Among the infected cases, multiple blood transfusions were seen only in 3 cases (2 positive for HBsAg and 1 for HCV). Among the three, one case with positive Anti-HCV underwent multiple blood transfusions and in the remaining two cases, blood transfusion was received only twice. The history of undergoing surgeries was obtained in nine cases. Among the 9 cases, HBV infection was seen in 4, HCV in 4, and dual infection was seen in one case. Twelve cases were diabetic, with HBV infection in 6, HCV in 5 cases, and dual infection in 1 case (Figure 3).
With respect to similar risk factors in the control group, 14 control patients had diabetes and 4 of them had history of undergoing surgery in the past. Only 1 control patient had history of undergoing blood transfusion (Figure 3).
Patients diagnosed with chronic renal failure (CRF) on maintenance haemodialysis pose a higher risk for acquiring HBV or HCV infections due to frequent use of blood and blood products and multiple invasive procedures performed in these patients . The literature review points to the fact that viral hepatitis is a serious threat for haemodialysis patients as 1.9% of all deaths among this population were related to the consequence of viral hepatitis .
The results from our study demonstrate that the occurrence of HBV and HCV infections in haemodialysis patients is 1.52% and 1.11%, respectively, which is lower than the rates reported from different studies all over the world and India [5–8]. An Indian study has reported the occurrence of HBV in haemodialysis to vary from 3.4% to 42%, much higher than that seen in our study . The lower rates of infection in our study might be due to decreased transfusion requirements owing to the availability of erythropoietin and better screening of blood and blood products for blood-borne infections. Introduction of vaccination for HBV, isolation of hepatitis B virus (HBV) positive patients, and regular surveillance for HBV infection at our centre could also have contributed for the lesser rates of infection.
Occurrence of HCV infection was much less than HBV in our study which was in accordance with a study conducted in Spain which reported lesser prevalence rates for HCV infection in haemodialysis (HD) patients . Another study showed a significant decline of hepatitis C infection among end-stage renal disease patients in Central Brazil, highlighting the importance of public health strategies such as screening for anti-HCV in blood banks and infection control measures for control and prevention of hepatitis C in the haemodialysis environment .
Since both of these viruses share a common mode of transmission, we looked for the occurrence of coinfections among the cases studied. Among the cases, dual infection with HBV and HCV was seen in two patients, 1 male and 1 female (2/45 = 4.4%). Study from the same centre on the occurrence of coinfections in the general population reported lower rates (1.68%) of dual infections . Studies from other centres in India have reported a varying prevalence of coinfections with HBV and HIV (9–40%) and for HCV and HIV (2–8%) .
The higher occurrence in our study may be due to the study population being restricted to haemodialysis patients and also due to the lesser sample size in the current study. Another factor contributing to the higher rates is the enhanced risk of coinfections among chronic renal failure patients on haemodialysis due to multiple transfusions and invasive procedure performed in these patients . However, dual infection with HBV and HCV in our study which was 4.4%, similar to the study conducted in Hyderabad .
The present study highlights the duration of dialysis as an important risk factor for infection among haemodialysis patients. This observation was in agreement with previous reports in Palestine, Moldavia, and other studies from different regions of the world [15–17]. Duration of dialysis is an important risk factor for acquiring infections as it is related to nosocomial transmission and dissemination of the infections in the dialysis units .
On comparison of AST and ALT values among cases and controls, it was found that cases had higher mean value. This can be explained on the basis of destruction of hepatocytes caused by the immune reaction of body responding to the hepatitis viruses leading to excessive release of the aminotransferases. These findings were in accordance with the studies conducted in Karachi and Jenin district and Gaza strip in Palestine [1, 18].
In our study, when compared with the control group, 67% of the patients on haemodialysis with HBV/HCV were found to have higher hemoglobin levels. This interesting finding was supported by few studies and was attributed to the increase in RBC counts after infection with hepatitis viruses and also to increased erythropoietin production after hepatic stimulation by chronic infection with hepatitis virus. However, the exact cause for the same is not yet established [19–22].
A study from our centre brings to light that HBV and HCV infections, though less common, continue to remain as an important causes of infection in haemodialysis patients. The risk of exposure increases with the number of dialysis sessions and is maximum in patients on maintenance haemodialysis. Interventions to reduce the occurrence of these infections are of utmost need to reduce the risk of long-term complications.
- J. Q. Abumwais and O. F. Idris, “Prevalence of hepatitis C, hepatitis B, and HIV infection among haemodialysis patients in Jenin District (Palestine),” Iranian Journal of Virology, vol. 4, no. 2, pp. 38–44, 2010.
- P. Bhaumik and K. Debnath, “Prevalence of hepatitis B and C among haemodialysis patients of Tripura, India,” Euroasian Journal of Hepato-Gastroenterology, vol. 2, no. 1, pp. 10–13, 2012.
- G. A. Reddy, K. V. Dakshinamurthy, P. Neelaprasad, T. Gangadhar, and V. Lakshmi, “Prevalence of HBV and HCV dual infection in patients on haemodialysis,” Indian Journal of Medical Microbiology, vol. 23, no. 1, pp. 41–43, 2005.
- A. Aghakhani, M. Banifazl, A. Eslamifar, F. Ahmadi, and A. Ramezani, “Viral hepatitis and HIV infection in hemodialysis patients,” Hepatitis Monthly, vol. 12, no. 7, pp. 463–464, 2012.
- A. E. O. Otedo, S. O. Mc'Ligeyo, F. A. Okoth, and J. K. Kayima, “Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country,” South African Medical Journal, vol. 93, no. 5, pp. 380–384, 2003.
- S. U. Busek, E. H. Babá, H. A. Tavares Filho et al., “Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil,” Memorias do Instituto Oswaldo Cruz, vol. 97, no. 6, pp. 775–778, 2002.
- S. K. Agarwal, S. C. Dash, and M. Irshad, “Hepatitis C virus infection during haemodialysis in India,” Journal of Association of Physicians of India, vol. 47, no. 12, pp. 1139–1143, 1999.
- A. Chowdhury, A. Santra, R. Chakravorty et al., “Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants,” Journal of Gastroenterology and Hepatology, vol. 20, no. 11, pp. 1712–1720, 2005.
- D. Saha and S. K. Agarwal, “Hepatitis and HIV infection during haemodialysis,” Journal of the Indian Medical Association, vol. 99, no. 4, pp. 194–199, 2001.
- M. Espinosa, A. Martín-Malo, R. Ojeda et al., “Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 685–689, 2004.
- M. A. S. Carneiro, S. A. Teles, M. A. Dias et al., “Decline of hepatitis C infection in hemodialysis patients in Central Brazil: a ten years of surveillance,” Memorias do Instituto Oswaldo Cruz, vol. 100, no. 4, pp. 345–349, 2005.
- K. Kosaraju, S. Padukone, and I. Bairy, “Co-infection with hepatitis viruses among HIV-infected individuals at a tertiary care centre in South India,” Tropical Doctor, vol. 41, no. 3, pp. 170–171, 2011.
- J. Tourret, I. Tostivint, S. T. du Montcel, et al., “Outcome and prognosis factors in HIV-infected haemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1241–1247, 2006.
- M. Chandra, M. N. Khaja, M. M. Hussain et al., “Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure,” Intervirology, vol. 47, no. 6, pp. 374–376, 2004.
- M. J. Zahedi, S. D. Moghaddam, S. M. Alavian, and M. Dalili, “Seroprevalence of hepatitis viruses B, C, D and HIV infection among hemodialysis patients in Kerman Province, South-East Iran,” Hepatitis Monthly, vol. 12, no. 5, pp. 339–343, 2012.
- A. Covic, L. Iancu, C. Apetrei et al., “Hepatitis virus infection in haemodialysis patients from Moldavia,” Nephrology Dialysis Transplantation, vol. 14, no. 1, pp. 40–45, 1999.
- D. N. Irish, C. Blake, J. Christophers, et al., “Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening,” Journal of Medical Virology, vol. 59, no. 2, pp. 135–140, 1999.
- A. E. Y. El-Ottol, A. A. Elmanama, and B. M. Ayesh, “Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine,” Virology Journal, vol. 7, p. 210, 2010.
- A. A. A. Sabry, K. F. El-Dahshan, K. M. Mahmoud, and A. A. El-Husseini, “Effect of HCV infection on hematocrit and hemoglobin level in Egyptian hemodialysis patients,” International Urology and Nephrology, vol. 41, no. 1, pp. 189–193, 2009.
- K. A. Alsaran, A. A. Sabry, A. H. Alghareeb, and G. Al Sadoon, “Effect of hepatitis C virus on hemoglobin and hematocrit levels in Saudi hemodialysis patients,” Renal Failure, vol. 31, no. 5, pp. 349–354, 2009.
- Y. L. Lin, C. W. Lin, C. H. Lee, I. C. Lai, H. H. Chen, and T. W. Chen, “Chronic hepatitis ameliorates anaemia in haemodialysis patients,” Nephrology, vol. 13, no. 4, pp. 289–293, 2008.
- M. Radovic, W. Jelkmann, L. Djukanovic, and V. Ostric, “Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection,” Journal of Interferon and Cytokine Research, vol. 19, no. 4, pp. 369–373, 1999.